

# Medicinal Products for Human Use - CZECH REPUBLIC

## Competent authority

### Contact Details

#### Contact Name 1

State Institute for Control of Drugs- SÚKL (Státní ústav pro kontrolu léčiv)

#### Phone

+420 272 185 111

#### Fax

+420 271 732 377

#### Email General

infos@sukl.cz

#### Address

Šrobárova 48

#### ZIP/City

100 41 Praha 10

#### Web address

<http://www.sukl.eu/medicines>

#### Additional Information

No local CAs existing.

### Trial Authorisation / Registration / Notification

#### Regulatory and ethics bodies involved in approval process

Competent Authority/-ies (CA)  
Ethics committee(s)

#### CA - Submission for authorisation mandatory for

Clinical IMP trials

#### CA - Registration/ notification without approval required for

—

#### CA - Submission required to

National CA

#### Additional Information

There are various types of Application:

Types of IMP obtained by biotechnology or containing substances of human or animal origin:

Type A: IMP is NOT authorised in the Czech Republic or in other EU Member States.

Type B: IMP is authorised in the Czech Republic or in other EU Member States, but not used in accordance with the terms of marketing authorization

Type C: IMP is authorised in the Czech Republic and used in accordance with the terms of marketing authorization

Accordingly, the approval mode (silent or explicit approval) and timelines may differ (further information available on SUKL website in section: Medicines > Clinical trial on pharmaceuticals > Details of clinical trials > Guidelines and Forms > KLH-20 version 5.)

Submission of Application	<p><b>Responsible for study submission</b></p> <p>Sponsor  Legal representative domiciled in the EU/EEA  Legal representative domiciled in the respective country</p> <p><b>Entitled to study submission</b></p> <p>—</p> <p><b>Prerequisites for submission</b></p> <p>—</p> <p><b>Guidance on submission of application</b></p> <p>KLH-20 Application for Authorisation/ Notification of Clinical Trials (detailed application guidance available on the SUKL website in its latest version)</p>
Submission Format	<p><b>Format option(s)</b></p> <p>Paper hardcopy  Data carrier (CD-rom/DVD)</p> <p><b>Preferred format</b></p> <p>—</p> <p><b>Guidance on submission format</b></p> <p>KLH-20 Application for Authorisation/ Notification of Clinical Trials (detailed application guidance available on the SUKL website in its latest version)</p>
Language of Submission	<p><b>Language(s) of application</b></p> <p>Czech, Slovak or English</p> <p><b>Preferred language of application</b></p> <p>—</p> <p><b>English accepted</b></p> <p>—</p> <p><b>Documents mandatory to be in official national language</b></p> <p>Protocol Summary  Information material, Documents and Forms intended for study participants and patient information</p> <p><b>Applicable national legal framework/ Reference</b></p> <p>KLH-20 (Guidance document providing detailed information on language of specific documents)</p>
Submission Fees	<p><b>Fees for trial submission mandatory</b></p> <p>Yes</p> <p><b>Fees</b></p> <p>Authorisation of clinical trial on MP (Type A): 67 300 CZK (2692€)  Notification of clinical trial on authorized MP (Type C): 15 800 CZK (632€)  Other notification of a clinical trial on MP: 33 900 CZK (1356€)  Substantial amendments: 15800 CZK (632€)  Academic clinical trials: exempt from fees</p> <p><b>Waiver for academic (non-commercial) studies possible</b></p> <p>Yes</p>

## **Official guidance on required fees**

SUKL guideline UST-29 or UST-24 (in Czech only) or SUKL website in English: Covering expenditures: Clinical trials etc. - status: 5.10.2013)

## **Additional Information**

Types of IMP obtained by biotechnology or containing substances of human or animal origin:

Type A: IMP is NOT authorised in the Czech Republic or in other EU Member States.

Type B: IMP is authorised in the Czech Republic or in other EU Member States, but not used in accordance with the terms of marketing authorization

Type C: IMP is authorised in the Czech Republic and used in accordance with the terms of marketing authorisation

## Timelines Authorisation

### **General timespan (max nr days)**

60 (IMP Type A+B) or 30 (IMP Type C)

### **Mode of approval (General)**

Explicit (IMP Type A) or Tacit (IMP Type B+C)

### **ATMP/GMO trials (max nr days)**

90

### **Mode of approval (ATMP/GMO trials)**

Explicit

### **External expert advice required (max nr days)**

180

### **Xenogeneic cell therapy (max nr days)**

—

### **Mode of approval (Xenogeneic cell therapy)**

—

### **Timespan counted from**

—

### **Applicable national legal framework/ Reference**

Section 55 Act on Pharmaceuticals

## **Additional Information**

Types of IMP obtained by biotechnology or containing substances of human or animal origin:

Type A: IMP is NOT authorised in the Czech Republic or in other EU Member States.

Type B: IMP is authorised in the Czech Republic or in other EU Member States, but not used in accordance with the terms of marketing authorization

Type C: IMP is authorised in the Czech Republic and used in accordance with the terms of marketing authorisation

## Amendments/ Substantial Amendments (SA)

### **Notification mandatory for**

Any substantial amendments

### **Authorisation mandatory for**

All clinical trials resp. investigations

### **Responsible for submission of SA**

Sponsor

**Timeline for approval of SA (max nr days)**

30 (silent approval)

**Guidance on submission of SA**

Modality: in writing, providing a rationale and a draft of the revised relevant part of the dossier.

**Applicable national legal framework/ Reference**

Section 56(1)&(2) Act on Pharmaceuticals  
Section 6 Decree on GCP

## Safety Reporting

**Responsible for AE reporting to CA**

Sponsor

**Sponsor must declare reportable events to**

—

**Reportable AEs**

SAE (Serious Adverse Event)  
SUSAR (Suspected Unexpected Serious Adverse Reaction)

**SUSAR being life-threatening or leading to death must be reported**

Immediately (without delay)  
Within a max of 7d upon first knowledge (+ 8d for additional information)

**All other SUSARs**

Immediately (without delay)  
Within a max of 15d upon first knowledge

**SAE /SADE must be reported**

—

**National standard reporting form available**

Only for reportable events occurring in the respective country

**Standard Reporting Form**

Electronic form available on the SUKL website (in Czech language only)

**Reporting format - Options**

Electronically

**Preferred format**

—

**Annual safety report shall be provided by sponsor to**

National CA

**Guidance on AE reporting procedure**

“KLH-21 -Reporting Adverse Reactions to Medicinal Products for Human Use in a Clinical Trial and to Medicinal Products without Marketing Authorisation” (available on SUKL website).  
<http://www.sukl.eu/medicines/klh-21-version-5>

**Applicable national legal framework/ Reference**

Act on Pharmaceuticals (No. 378/2007)  
Decree on GCP (No. 226/2008)

## Additional Information

The Annual Safety Report has to be submitted electronically to the CA (klinsekret(at)sukl.cz).

The sponsor will provide a report for the EudraVigilance database. Those sponsors who do not have access to the electronic exchange of SUSARs with the EudraVigilance database and SUKL - i.e. particularly the sponsors of grant clinical trials not backed by pharmaceutical companies, i.e. the grant studies presented by physicians or professional societies, can request SUKL in a written request to make input into the EudraVigilance database on their behalf.

Reporting format to EudraVigilance Database: online

## Investigator shall report SAE to

–

## Reporting timeline

–

End of Trial

## End of trial declaration mandatory for

All clinical trials requiring authorisation by CA

## Responsible for End of trial declaration

Sponsor

## Regular Termination - Declaration timespan (max nr days)

90

## Timespan counted from

–

## Early/premature Termination - Declaration timespan (max nr days)

15

## Reasons for early termination shall be clearly stated

Yes

## Guidance on End of trial declaration

Section 18 and Annex 8 Decree on GCP

## Applicable national legal framework/ Reference

Section 56(5) Act on Pharmaceuticals  
Section 18 and Annex 8 Decree on GCP

## Ethics committee

Contact Details

### Contact Name 1

List of independent Ethics Committees on SUKL website

### Contact Name 2

(1) Multicentric Ethics Committees (MECs)

### Contact Name 3

(2) Local Ethics Committees (established at healthcare facilities)

### Web address

<http://www.sukl.eu/sukl/ethic-committies>

### Additional Information

More than 100 local ECs and 11 MECs.

Ethical Review – General	<p><b>Submission for Ethical review mandatory for</b></p> <p>All clinical trials on Medicinal Products (MP)</p> <p><b>Submission to CA and EC to be performed in the following order</b></p> <p>In parallel</p> <p><b>Regulatory and ethics bodies involved in approval process</b></p> <p>Competent Authority/-ies (CA) Ethics committee(s)</p>
Single-Centre Studies - Ethical Review	<p><b>Ethical approval (favourable opinion) to be obtained from</b></p> <p>Local EC</p> <p><b>Additional Information</b></p> <p>There are more than 100 local ECs in Czech republic which review all single-site research projects at the relevant institution. If there is no local EC established at the relevant site, the applicant shall apply with the geographically closest EC.</p>
Multi-Centre Studies - Ethical Review	<p><b>Ethical approval (favourable opinion) required from</b></p> <p>Lead EC (authorised to issue a single opinion)</p> <p><b>Submission of application required to</b></p> <p>Multicentric Ethics Committees (MECs) + All concerned local ECs of participating sites</p> <p><b>Additional Information</b></p> <p>The applicant needs to inform all relevant ECs on the involvement of other ECs (multicentric about local and vice versa). The multisite clinical trial ethical review is done by an ethics committee for multi-site studies (MEC) and also by each of the relevant local EC. (Section 54 of Act No 378/2007 Coll. on Amendment to the Act on Pharmaceuticals)</p>
Submission of Application	<p><b>Responsible for study submission</b></p> <p>Sponsor</p> <p><b>Entitled to study submission</b></p> <p>Sponsor Investigator</p> <p><b>Prerequisites for submission / approval</b></p> <p>–</p> <p><b>Guidance on study submission</b></p> <p>KLH-EC-01 - Application for Ethics Committee Opinion on the Conduct of a Clinical Trial in the Czech Republic – requirements governing the documentation to be submitted</p> <p><b>Applicable national legal framework/ Reference</b></p> <p>Section 5.1 Decree on GCP</p>
Submission Format	<p><b>Format option(s)</b></p> <p>Paper hardcopy Electronically</p> <p><b>Preferred format</b></p> <p>–</p>

	<p><b>Guidance on submission format</b></p> <p>"KHL-EC-01 - Application for Ethics Committee opinion on the conduct of a clinical trial in the Czech Republic" (detailed guidelines on EC application)</p>
Language of Submission	<p><b>Language(s) of application</b></p> <p>Official national language English</p> <p><b>Preferred language of application</b></p> <p>—</p> <p><b>English accepted</b></p> <p>Partly, not for all documents</p> <p><b>Documents mandatory to be in official national language</b></p> <p>Protocol Summary Information material, Documents and Forms intended for study participants and patient information EC clinical trial questionnaire</p>
Submission Fees	<p><b>Fees for Ethical review mandatory</b></p> <p>Yes</p> <p><b>Waiver for academic (non-commercial) studies possible</b></p> <p>Yes</p> <p><b>Fees for Ethical review</b></p> <p>Fees for evaluation (in CZK -VAT included)</p> <p>EC in role of MEC: Multicentric clinical trial (up to 10 centers): 48 000 CZK (approx 1600 EURO) For every center : 6 000 CZK (approx 220 EURO) For every additional center (from 11th site) : 4 800 CZK (approx 180 EURO) Evaluation of amendments: 6 000 CZK (approx 220 EURO)</p> <p>EC acting as LEC in a multicentric study: Approval for a single local study site: 12 000 CZK (approx 440 EURO)</p> <p>Monocentric study: 24 000 CZK (approx 880 EURO) (if study is extended to other sites and EC takes over the function as MEC: + 24 000 CZK) Evaluation of revised application: 6 000 CZK</p>
Timelines Ethical Review	<p><b>General timespan for single-centre studies (max nr days)</b></p> <p>60</p> <p><b>General timespan for multi-centre studies (max nr days)</b></p> <p>60</p> <p><b>ATMP/GMO trials (max nr days)</b></p> <p>90</p> <p><b>External expert advice required: Timespan (max nr days)</b></p> <p>180</p> <p><b>Xenogeneic cell therapy: Timespan (max nr days)</b></p> <p>No time limit</p> <p><b>Clock-stop possible if complementary information requested</b></p> <p>Yes</p>

	<p><b>Timespan counted from</b></p> <p>Date of submission of valid application</p> <p><b>Applicable national legal framework/ Reference</b></p> <p>Section 53 (9&amp;10) Act on Pharmaceuticals  Section 5 (5) Decree on GCP  KLH-11: Guideline on EC (Translation of Chapter 3. of ICH Guideline for Good Clinical Practice (E6, May 1, 1996))</p> <p><b>Additional Information</b></p> <p>There are set dates for EC meetings about once a month. Deadline for submission is usually about 20 days prior to the meeting. The EC provide its opinion to the sponsor and to CA. For more detailed info see Guidance “KLH-EC-01 – Application for Ethics Committee opinion on the conduct of a clinical trial in the Czech Republic”</p>
Amendments/ Substantial Amendments (SA)	<p><b>Ethical review mandatory for</b></p> <p>Any substantial amendments</p> <p><b>Responsible for notification of SA</b></p> <p>Sponsor</p> <p><b>Timeline Ethical review of SA (max nr days)</b></p> <p>35</p>
Safety Reporting	<p><b>Reportable AEs</b></p> <p>SAE (Serious Adverse Event)  SUSAR (Suspected Unexpected Serious Adverse Reaction)</p> <p><b>Investigator shall report SAE to</b></p> <p>Sponsor</p> <p><b>Reporting timeline</b></p> <p>Immediately (without delay)</p> <p><b>Responsible for AE reporting to relevant EC(s)</b></p> <p>Sponsor</p> <p><b>SUSAR being life-threatening or leading to death must be reported</b></p> <p>Within a max of 7d upon first knowledge (+ 8d for additional information)</p> <p><b>All other SUSAR must be reported</b></p> <p>Within a max of 15d upon first knowledge</p> <p><b>SAE/SADE must be reported</b></p> <p>–</p> <p><b>National Standard Reporting form available</b></p> <p>–</p> <p><b>Reporting format - Options</b></p> <p>–</p> <p><b>Preferred reporting format</b></p> <p>–</p> <p><b>Provision of Annual safety report mandatory</b></p> <p>Yes</p>



### **Guidance on AE reporting procedure**

A detailed guideline on AE reporting obligations published by SUKL is available on the website:

"KLH-21 -Reporting Adverse Reactions to Medicinal Products for Human Use in a Clinical Trial and to Medicinal Products without Marketing Authorisation"

### **National legal framework in place**

Yes

### **Applicable national legal framework/ Reference**

Section 58(4)&(5) Act on Pharmaceuticals

### **Additional Information**

ad Annual Safety Report: A summary of the Annual Safety Report provided to the CA has to be submitted to the local EC or the MEC only.

End of Trial

### **End of trial Declaration mandatory**

Yes

### **Responsible for End of trial Declaration**

—

### **Regular Termination - Declaration timespan (max nr days)**

—

### **Timespan counted from**

—

### **Early/premature Termination - Declaration timespan (max nr days)**

15

### **Reasons for early termination shall be clearly stated**

Yes

### **Applicable national legal framework/ Reference**

Section 56(5) Act on Pharmaceuticals;  
Section 18 and Annex 8 Decree on GCP (further information about completion, suspension or early termination)

## **Study specific Requirements**

Study Participants -  
Informed Consent (IC)

### **Standard IC form (ICF)**

KLH-22: Guidance document on "Requirements Governing the Text of Patient Information Leaflet Trial Subject Information Sheet /Informed Consent Form" is available on SUKL website in section: Medicines / Clinical trial on pharmaceuticals / Details of clinical trials / Guidelines and Forms

### **Informed Consent - Definition/ Requirements**

An expression of willingness to take part in a clinical trial which shall be

1. written,
2. dated and signed by the trial subject in his/her own hand,
3. taken freely after being duly informed of the nature, significance, implications, and risks of the clinical trial,
4. appropriately documented,
5. granted by a person capable of giving the informed consent or where the person is not capable of giving the informed consent by his or her guardian; if the person concerned is unable to write, oral consent in the presence of at least one witness may be given and a written record thereof taken;

### **Applicable national legal framework/ Reference**

Section 51 (2h) Act on Pharmaceuticals 2007 (en)

Study Participants -  
Vulnerable Population

### **Minors / Children - Studies allowed**

Yes  
Special provisions apply

#### **Specific provision**

The consent is granted by the legal guardian(s) (in principle the parents). The consent must correspond to the minor's presumed will where such a will can be ascertained (informed assent).

#### **Legal framework/Reference (Minors/Children)**

Section 52 (6) Act on Pharmaceuticals

### **Incapacitated persons - Studies allowed**

Yes  
Special provisions apply

#### **Legal framework / Reference (Incapacitated persons)**

Section 52(7) & (8) Act on Pharmaceuticals

### **Emergency situations - Studies allowed**

Yes  
Special provisions apply

### **Emergency situation without prior consent of patient or proxy - Studies allowed**

Yes  
With limitations

### **Conditions allowing trial participation in emergency setting without prior consent**

In Czech Republic, there is allowed to include patients to clinical trial without his/her prior consent. But there is required the consent of legal guardian (person authorized by the court). If the legal representative is not available, it is allowed to include patient to clinical trial without consent of legal guardian, but there is necessary to get consent (legal guardian or patient) as soon as it becomes possible. The CA and EC must have provided approval of the trial before and in the study protocol there must be described this situation – how to get the ICF in emergency situation.

#### **Legal framework / Reference (Emergency Situation)**

Section 52(9) Act on Pharmaceuticals

### **Pregnant or breastfeeding women - Studies allowed**

No

#### **Specific provisions**

The conduct of a clinical trial in pregnant or lactating women is prohibited

#### **Legal framework / Reference (Pregnant or breastfeeding women)**

Section 52 (2) b) Act on Pharmaceuticals

### **Applicable legal framework / Reference (Vulnerable Population)**

The conduct of a clinical trial in vulnerable subjects is permissible only if expected to provide preventive or therapeutic benefits for these persons (pursuant to Section 52 Act on Pharmaceuticals).

Study Participants -  
Compensation &  
Reimbursement

### **Reimbursement for study participants**

Optional

### **Compensation is limited to/provided for**

—

**Additional Information**

Compensations, insurance, and remunerations as per paragraph 7, (h) to (j) must be assessed by the ethics committee with respect to the protection of the rights, safety, and health of the trial subjects, within the scope stipulated by the implementing legal regulation. (Section 53 (8) Act of Pharmaceuticals)

## Data Protection

**Notification to DP Authority/ Ombudsmann is mandatory**

No

**Approval/ authorisation required**

No

**Specific notification timelines before operations start**

–

**Language of notification**

–

**Notification format**

–

**Data Protection Authority/ Agency - Contact Details**

The Office for Personal Data Protection

**Phone**

+420 234 665 111

**Fax**

+420 234 665 444

**E-Mail**

posta@uouu.cz

**Web address**

<https://www.uouu.cz/en/>

**Address**

Pplk. Sochora 27

**ZIP/City**

170 00 Praha 7

**Country**

Czech Republic (CZ)

**Legal framework (on safeguarding the collection, handling, recording, keeping and/or processing of any clinical trial related data and patient files)**

–

## Insurance

**Liability insurance or alternative arrangements for damages mandatory for**

Investigator(s)  
Sponsor  
Study participants

**Responsible for covering insurance**

Sponsor

**Applicable national legal framework/ Reference**

Section 52 (3f) Act on Pharmaceuticals

**Additional Information**

The insurance shall cover the damages in the event of the death of the trial subject or in the event of an injury to the health of the trial subject arising from the conduct of the clinical trial.

**National legislation**

General Information:  
Applicable Legislation &  
Conventions

**Official website providing relevant national legislation**

<http://www.sukl.eu/sukl/legislation-of-the-czech-republic>

**Additional Information**

Convention on Human Rights and Biomedicine/ Oviedo Convention:  
Communication from the Ministry of Foreign Affairs No. 96/2001 Coll. ms, the adoption of the Convention for the Protection of Human Rights and dignity of human beings and in the context of the Application of Biology and Medicine

Clinical Trials on IMPs in  
Humans

**Applicable national regulations**

Transposition of (CT) Directive 2001/20/EC  
Transposition of (GCP) Directive 2005/28/EC  
Other

**Transposition of (CT) Directive 2001/20/EC (or comparable national legal framework)**

Act No. 378/2007 Coll., on Pharmaceuticals and on Amendments to Some Related Acts (Act on Pharmaceuticals), as amended.

**Applicable to ATMP/ GMO trials**

Yes

**Transposition of (GCP) Directive 2005/28/EC**

Incorporated in transposition act(s) of Directive 2001/20/EC

**Other applicable regulations/ implementing provisions (Acts, laws, decrees, ordinances, circulars, etc)**

- Decree No. 226/2008 Coll., on good clinical practice and detailed conditions of clinical trials on medicinal products ("Decree on GCP"): implementing provisions of Act on Pharmaceuticals (available in English)  
- Decree No. 228/2008 Coll., on marketing authorisation of medicinal products

**Additional Information**

A complete list of implementing regulations and decrees is provided on the SÚKL website in "Legislation and guidelines".

Radiation &  
Radiotherapy

**Use of radiation or radioactive compounds - Specific requirements**

Yes

**Applicable legal framework**

Section 18 + 55 Act on Pharmaceuticals

**Additional Information**

The State Office for Nuclear Safety shall provide opinions on the marketing authorisations and clinical trials of radiopharmaceuticals. SÚKL shall request the opinion of the State Office for Nuclear Safety, which shall issue such opinion within 30 days of delivery of the request.

Data Protection

**Legal framework (on safeguarding the collection, handling, recording, keeping and/or processing of any clinical trial related data and patient files)**

National Data Protection Act

**National DP act**

Act No. 101/2000 Coll., on the protection of personal data (2000)

## Definition

IMP/IMP Study

**IMP - Definition available in national law**

Yes

**IMP - Definition**

Definition according to section 51(2c) Act No. 378/2007 Coll., on Pharmaceuticals:

a pharmaceutical form of an active substance or product obtained through technological processing of mere excipients (a placebo) which are being tested or used for comparison in a clinical trial; an investigational medicinal product may also be a product already with a marketing authorisation but used or assembled (including changes to composition of the pharmaceutical form or packaging) in a way different from the authorised form of the medicinal product or when used out of the authorised indication(s) or for the purposes to gain further information about the authorized presentation of the medicinal product.

**IMP Study - Definition available in national law**

Yes

**IMP Study - Definition**

Definition according to section 51(2) Act No. 378/2007 Coll., on Pharmaceuticals:

"A clinical trial shall mean any systematic testing conducted on trial subjects intended to:

1. discover or verify the clinical, pharmacological or other pharmacodynamic effects,
2. identify any adverse reactions,
3. study absorption, distribution, metabolism or excretion of one or more investigational

medicinal product(s) with the objective of ascertaining its (their) safety or efficacy, including

clinical trials conducted at one or more trial sites in the Czech Republic or in the Member

States, where applicable